Page 587 - Basic _ Clinical Pharmacology ( PDFDrive )

CHAPTER 31 Opioid Agonists & Antagonists 573

PREP AR A TIONS A V AIL ABLE *

GENERIC NAME AVAILABLE AS GENERIC NAME AVAILABLE AS
ANALGESIC OPIOIDS OTHER ANALGESICS
Alfentanil Generic, Alfenta Tapentadol Nucynta
Buprenorphine Buprenex, others, Butrans (transdermal) Tramadol Generic, Ultram, others
Butorphanol Generic, Stadol, Stadol NS (nasal) Ziconotide Prialt
Codeine (sulfate or Generic ANALGESIC COMBINATIONS ‡
phosphate) Codeine/acetaminophen Generic, Tylenol with
Fentanyl Generic, Duragesic (transdermal). Codeine, others
Fentanyl Buccal, Fentanyl Actiq Codeine/aspirin Generic, Empirin Compound, others
(lozenge)
Hydromorphone Generic, Dilaudid, others Hydrocodone/ Generic, Norco, Vicodin, Lortab, others
acetaminophen
Levomethadyl acetate † Orlaam Hydrocodone/ibuprofen Vicoprofen
Morphine sulfate Oxycodone/ Generic, Percocet, Tylox, others
Oral, rectal, parenteral Generic acetaminophen
Oral sustained-release Avinza, Kadian Oxycodone/aspirin Generic, Percodan
capsules OPIOID ANTAGONISTS
Oral extended-release Embeda
capsules (morphine Alvimopan Entereg
sulfate/naltrexone HCl) Methylnaltrexone Relistor
Nalbuphine Generic, Nubain Nalmefene Revex
Oxycodone Generic, OxyContin (sustained release) Naloxone Generic, Narcan
Oxymorphone Generic, Numorphan, others Naltrexone Generic, ReVia, Depade, Vivitrol
Pentazocine Talwin ANTITUSSIVES
Remifentanil Generic, Ultiva Codeine Generic
Sufentanil Generic, Sufenta Dextromethorphan Generic, Benylin DM, Delsym, others
*
Antidiarrheal opioid preparations are listed in Chapter 62.
†
Orphan drug approved only for the treatment of narcotic addiction.
‡ Dozens of combination products are available; only a few of the most commonly prescribed are listed here. Codeine combination products available in several strengths are
usually denoted No. 2 (15 mg codeine), No. 3 (30 mg codeine), and No. 4 (60 mg codeine). Prescribers should be aware of the possible danger of renal and hepatic injury with
acetaminophen, aspirin, and nonsteroidal anti-inflammatory drugs contained in these analgesic combinations.

REFERENCES Fields HL, Basbaum AI: Central nervous system mechanisms of pain modulation.
Angst MS, Clark JD: Opioid-induced hyperalgesia. Anesthesiology 2006;104:570. In: Wall PD, Melzack R (editors): Textbook of Pain. Churchill Livingstone,
1999.
Anton RF: Naltrexone for the management of alcohol dependence. N Engl J Med Fillingim RB, Gear RW: Sex differences in opioid analgesia: Clinical and experi-
2008;359:715. mental findings. Eur J Pain 2004;8:413.
Basbaum AI et al: Cellular and molecular mechanisms of pain. Cell 2009;139:267. Fischer BD, Carrigan KA, Dykstra LA: Effects of N-methyl-d-aspartate receptor
Basbaum AI, Jessel T: The perception of pain. In: Kandel ER et al (editors): Prin- antagonists on acute morphine-induced and l-methadone-induced antino-
ciples of Neural Science, 4th ed. McGraw-Hill, 2000. ciception in mice. J Pain 2005;6:425.
Benedetti C, Premuda L: The history of opium and its derivatives. In: Benedetti Goldman D, Barr CS: Restoring the addicted brain. N Engl J Med 2002;347:843.
C et al (editors): Advances in Pain Research and Therapy, vol 14. Raven Press, Inui S: Nalfurafine hydrochloride for the treatment of pruritus. Expert Opin
1990. Pharmacother 2012;13:1507.
Bolan EA, Tallarida RJ, Pasternak GW: Synergy between mu opioid ligands: Joly V et al: Remifentanil-induced postoperative hyperalgesia and its prevention
Evidence for functional interactions among mu opioid receptor subtypes. with small-dose ketamine. Anesthesiology 2005;103:147.
J Pharmacol Exp Ther 2002;303:557. Julius D, Basbaum AI: Molecular mechanisms of nociception. Nature
Chu LF, Angst MS, Clark D: Opioid-induced hyperalgesia in humans: Molecular 2001;413:203.
mechanisms and clinical considerations. Clin J Pain 2008;24:479. Kalso E et al: No pain, no gain: Clinical excellence and scientific rigour—Lessons
Curran MP et al: Alvimopan. Drugs 2008;68:2011. learned from IA morphine. Pain 2002;98:269.
Dahan A et al: Sex-specific responses to opiates: Animal and human studies. Kharasch ED et al: Methadone pharmacogenetics: CYP2B6 polymorphisms
Anesth Analg 2008;107:83. determine plasma concentrations, clearance, and metabolism. Anesthesiol-
Davis MP, Walsh D: Methadone for relief of cancer pain: A review of pharmaco- ogy 2015;123:1142.
kinetics, pharmacodynamics, drug interactions and protocols of administra- Kiefer BL: Opioids: First lessons from knockout mice. Trends Pharmacol Sci
tion. Support Care Cancer 2001;9:73. 1999;20:19.
Ferner RE, Daniels AM: Office-based treatment of opioid-dependent patients. N Kim JA et al: Morphine-induced receptor endocytosis in a novel knockin mouse
Engl J Med 2003;348:81. reduces tolerance and dependence. Curr Biol 2008;18:129.
Ferrante FM: Principles of opioid pharmacotherapy: Practical implications of basic Lai J et al: Pronociceptive actions of dynorphin via bradykinin receptors. Neurosci
mechanisms. J Pain Symptom Manage 1996;11:265. Lett 2008;437:175.